Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 17/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 9/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395478 | 1.00 | CREBBP (0.41) | CREBBPCCNCCDK8BRD4FGFR3 | |
| SCHEMBL31496189 | 0.82 | TBK1 (0.43) | CREBBPBRD4 | |
| SCHEMBL28649787 | 0.79 | CREBBP (0.41) | CREBBPBRD4EP300 | |
| SCHEMBL31692747 | 0.77 | GPR119 (0.42) | — | |
| SCHEMBL17785637 | 0.75 | CREBBP (0.50) | CREBBPBRD4EP300 | |
| SCHEMBL29403112 | 0.75 | CREBBP (0.50) | CREBBPBRD4EP300 | |
| SCHEMBL30395928 | 0.74 | PDK4 (0.47) | — | |
| SCHEMBL25193494 | 0.74 | PDK4 (0.47) | — | |
| SCHEMBL31496201 | 0.73 | MGLL (0.40) | CREBBPBRD4 | |
| SCHEMBL23930186 | 0.72 | KDM4E (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4140996-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | EP300, CREBBP, BPTF | CREBBP 2/4885CCNC 3569/4885CDK8 2505/4885 |
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | EP300, CREBBP, BPTF | CREBBP 2/4885CCNC 3569/4885CDK8 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.